Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Prostate Cancer

Free Subscription Articles published in Cancer Lett Retrieve available abstracts of 46 articles: HTML format

Single Articles

June 2026
1. JIANG Y, Cheng S, Zhang CY, Jin X, et al
   HOX code-based stratification reveals RUNX1T1-HDAC reprogramming as a targetable driver of lineage plasticity across cancers.
   Cancer Lett. 2026;648:218465.
   PubMed     Abstract available
   
   
   April 2026
2. ALI A, Di Pastena F, Biziotis OD, Wang S, et al
   Canagliflozin Is a Novel Androgen Receptor Pathway Inhibitor for Castrate-Sensitive and Castrate-Resistant Prostate Cancer.
   Cancer Lett. 2026 Apr 24:218535. doi: 10.1016/j.canlet.2026.218535.
   PubMed     Abstract available
   
   
   March 2026
3. YAN H, Mao AW, Li D, Fu G, et al
   AI-discovered cellular morphometric biomarkers in needle biopsy of prostate cancer predict neoadjuvant androgen deprivation therapy response and enable therapeutic targeting of mTOR in androgen deprivation therapy-resistant tumors.
   Cancer Lett. 2026 Mar 24:218447. doi: 10.1016/j.canlet.2026.218447.
   PubMed     Abstract available
   
   
   February 2026
4. XIE Z, Li S, Yang J, Zhang Z, et al
   SNHG18 deficiency reprograms arginine metabolism to foster an immunosuppressive microenvironment in prostate cancer bone metastasis.
   Cancer Lett. 2026;644:218326.
   PubMed     Abstract available
   
   
   
5. SHIGETA K, Takamori S, Ozawa H, Haratake N, et al
   M1C Mediates LINE-1 Transcription in PARP Inhibitor-Treated Prostate Cancer Cells.
   Cancer Lett. 2026 Feb 12:218320. doi: 10.1016/j.canlet.2026.218320.
   PubMed     Abstract available
   
   
   January 2026
6. MAK CSL, Zhu M, Fu J, Liang X, et al
   KDM4A promotes NEPC progression through regulation of MYC expression.
   Cancer Lett. 2026;638:218184.
   PubMed     Abstract available
   
   
   
7. ZHANG Y, Zhao H, Xu P, Liu K, et al
   The Zeb1/system X(c)(-) axis safeguards iron-loaded cancer-associated fibroblasts against ferroptosis and promotes immunosuppression in prostate cancer.
   Cancer Lett. 2026;639:218243.
   PubMed     Abstract available
   
   
   December 2025
8. GUAN Y, Cao F, Luo Y, Li J, et al
   High-fat diet induced ECM remodeling attenuates chemosensitivity in prostate cancer via activating Piezo1-dependent mitochondria-ER contacts.
   Cancer Lett. 2025 Dec 9:218204. doi: 10.1016/j.canlet.2025.218204.
   PubMed     Abstract available
   
   
   November 2025
9. MATOS AC, Lima M, Miranda-Goncalves V, Indraccolo S, et al
   Overcoming Radioresistance in Prostate Cancer by Targeting DNA Damage Repair.
   Cancer Lett. 2025 Nov 28:218183. doi: 10.1016/j.canlet.2025.218183.
   PubMed     Abstract available
   
   
   October 2025
10. NIKHIL K, Kamra M, Raza A, Shah K, et al
    Corrigendum to "Negative cross talk between LIMK2 and PTEN promotes castration resistant prostate cancer pathogenesis in cells and in vivo" [Cancer Lett. 498 (2021) 1-18].
    Cancer Lett. 2025 Oct 17:218044. doi: 10.1016/j.canlet.2025.218044.
    PubMed    
    
    
    September 2025
11. AHMAD G, El Sadda R, Botchkina G, Ojima I, et al
    Corrigendum to "Nanoemulsion formulation of a novel taxoid DHA-SBT-1214 Inhibits prostate cancer stem cell-induced tumor growth" [Cancer Lett. 2017 Aug 11;406:71-80].
    Cancer Lett. 2025 Sep 23:218043. doi: 10.1016/j.canlet.2025.218043.
    PubMed    
    
    
    August 2025
12. NIKHIL K, Chang L, Viccaro K, Jacobsen M, et al
    Corrigendum to "Identification of LIMK2 as a therapeutic target in castration resistant prostate cancer" [Cancer Lett 448 (2019)182-196].
    Cancer Lett. 2025 Aug 25:217999. doi: 10.1016/j.canlet.2025.217999.
    PubMed    
    
    
    
13. GU R, Janknecht J, Oh S, Jiang H, et al
    Anti-tumor activity of CDYL2b in prostate cancer.
    Cancer Lett. 2025 Aug 12:217987. doi: 10.1016/j.canlet.2025.217987.
    PubMed     Abstract available
    
    
    
14. THARIAN L, Verma S, Feinberg D, Parameswaran R, et al
    Chimeric Antigen Receptor-Engineered (CAR)-T Cell Therapy for Metastatic Prostate Cancer.
    Cancer Lett. 2025 Aug 12:217986. doi: 10.1016/j.canlet.2025.217986.
    PubMed     Abstract available
    
    
    July 2025
15. CHENG B, Luo T, Wu Y, Hu J, et al
    Urinary Exosomal FAM153C-RPL19 Chimeric RNA as a Diagnostic and Prognostic Biomarker for Prostate Cancer in Chinese Patients.
    Cancer Lett. 2025 Jul 18:217938. doi: 10.1016/j.canlet.2025.217938.
    PubMed     Abstract available
    
    
    
16. MOLONY RD, Akash MMH, Kerns SL, Marples B, et al
    Extracellular vesicle proteomics identify neutrophils as potential mediators of bladder radiotoxicity in prostate cancer.
    Cancer Lett. 2025;631:217931.
    PubMed     Abstract available
    
    
    
17. SONG Y, Zhang C, Shao D, Song X, et al
    CircRHOBTB3 suppresses MAOA by promoting cytoplasmic retention of NONO to inhibit prostate cancer proliferation and metastasis.
    Cancer Lett. 2025;631:217910.
    PubMed     Abstract available
    
    
    
18. DENG K, Pallmann N, Livgard M, Kildal W, et al
    Endoplasmic Reticulum Stress-Driven Nucleotide Catabolism Fuels Prostate Cancer.
    Cancer Lett. 2025 Jul 3:217888. doi: 10.1016/j.canlet.2025.217888.
    PubMed     Abstract available
    
    
    June 2025
19. ZHANG M, Xu Z, Cao Y, Gao C, et al
    Analysis and characterization of extrachromosomal circular DNA in prostate cancer: Potential biomarker discovery from urine, plasma, and tumor samples.
    Cancer Lett. 2025;628:217875.
    PubMed     Abstract available
    
    
    May 2025
20. JIANG H, Zeng Y, Ning W, Hong J, et al
    Ketogenesis instigates immune suppression in enzalutamide resistant prostate cancer via OTUD7B beta-hydroxybutyrylation.
    Cancer Lett. 2025 May 18:217808. doi: 10.1016/j.canlet.2025.217808.
    PubMed     Abstract available
    
    
    April 2025
21. CAI S, Deng Y, Zou Z, Tian W, et al
    Metformin inhibits the progression of castration resistant prostate cancer by regulating PDE6D induced purine metabolic alternation and cGMP / PKG pathway activation.
    Cancer Lett. 2025 Apr 9:217694. doi: 10.1016/j.canlet.2025.217694.
    PubMed     Abstract available
    
    
    February 2025
22. CHAN HY, Wang Q, Howie A, Bucci J, et al
    Extracellular vesicle biomarkers redefine prostate cancer radiotherapy.
    Cancer Lett. 2025 Feb 18:217568. doi: 10.1016/j.canlet.2025.217568.
    PubMed     Abstract available
    
    
    
23. SUBRAMANIAM S, Jeet V, Gunter JH, Clements JA, et al
    Lactoferrin-Encapsulated Dichloroacetophenone (DAP) nanoparticles enhance drug delivery and anti-tumor efficacy in prostate cancer.
    Cancer Lett. 2025 Feb 7:217522. doi: 10.1016/j.canlet.2025.217522.
    PubMed     Abstract available
    
    
    January 2025
24. HINDES MT, McElligott AM, Best OG, Ward MP, et al
    Metabolic reprogramming, malignant transformation and metastasis: lessons from chronic lymphocytic leukaemia and prostate cancer.
    Cancer Lett. 2025 Jan 2:217441. doi: 10.1016/j.canlet.2025.217441.
    PubMed     Abstract available
    
    
    November 2024
25. LIU R, Zou Z, Zhang Z, He H, et al
    Evaluation of glucocorticoid-related genes reveals GPD1 as a therapeutic target and regulator of sphingosine 1-phosphate metabolism in CRPC.
    Cancer Lett. 2024;605:217286.
    PubMed     Abstract available
    
    
    
26. MUNIYAN S, Vengoji R, Nimmakayala RK, Seshacharyulu P, et al
    PAF1-mediated transcriptional reprogramming confers docetaxel resistance in advanced prostate cancer.
    Cancer Lett. 2024 Nov 25:217355. doi: 10.1016/j.canlet.2024.217355.
    PubMed     Abstract available
    
    
    
27. STEINER L, Eldh M, Offens A, Veerman RE, et al
    Protein profile in urinary extracellular vesicles is a marker of malignancy and correlates with muscle invasiveness in urinary bladder cancer.
    Cancer Lett. 2024;609:217352.
    PubMed     Abstract available
    
    
    October 2024
28. GURUVAYURAPPAN GK, Frankenbach-Desor T, Laubach M, Klein A, et al
    Clinical Challenges in Prostate Cancer Management: Metastatic Bone-tropism and The Role of Circulating Tumor Cells.
    Cancer Lett. 2024 Oct 30:217310. doi: 10.1016/j.canlet.2024.217310.
    PubMed     Abstract available
    
    
    August 2024
29. HE Q, Zhang Y, Li W, Chen S, et al
    Inhibition of PRMT5 moderately suppresses prostate cancer growth in vivo but enhances its response to immunotherapy.
    Cancer Lett. 2024;602:217214.
    PubMed     Abstract available
    
    
    
30. WANG X, Zhang L, Cheng L, Wang Y, et al
    Extracellular Vesicle-derived Biomarkers in Prostate Cancer Care: Opportunities and Challenges.
    Cancer Lett. 2024 Aug 12:217184. doi: 10.1016/j.canlet.2024.217184.
    PubMed     Abstract available
    
    
    
31. LIU D, Wang L, Guo Y
    Advances in and Prospects of Immunotherapy for Prostate Cancer.
    Cancer Lett. 2024 Aug 8:217155. doi: 10.1016/j.canlet.2024.217155.
    PubMed     Abstract available
    
    
    June 2024
32. LIU YN, Liu MK, Wen YC, Li CH, et al
    Binding of interleukin-1 receptor antagonist to cholinergic receptor muscarinic 4 promotes immunosuppression and neuroendocrine differentiation in prostate cancer.
    Cancer Lett. 2024 Jun 28:217090. doi: 10.1016/j.canlet.2024.217090.
    PubMed     Abstract available
    
    
    
33. CLARK A, Villarreal MR, Huang SB, Jayamohan S, et al
    Targeting S6K/NFkappaB/SQSTM1/Poltheta signaling to suppress radiation resistance in Prostate Cancer.
    Cancer Lett. 2024 Jun 24:217063. doi: 10.1016/j.canlet.2024.217063.
    PubMed     Abstract available
    
    
    
34. LIU C, Chen J, Cong Y, Chen K, et al
    PROX1 drives neuroendocrine plasticity and liver metastases in prostate cancer.
    Cancer Lett. 2024 Jun 18:217068. doi: 10.1016/j.canlet.2024.217068.
    PubMed     Abstract available
    
    
    
35. CHEN HJ, Yu MM, Huang JC, Lan FY, et al
    SLC4A4 is a novel driver of enzalutamide resistance in prostate cancer.
    Cancer Lett. 2024 Jun 14:217070. doi: 10.1016/j.canlet.2024.217070.
    PubMed     Abstract available
    
    
    May 2024
36. KAUSHAL JB, Takkar S, Batra SK, Siddiqui JA, et al
    Diverse landscape of genetically engineered mouse models: Genomic and molecular insights into prostate cancer.
    Cancer Lett. 2024;593:216954.
    PubMed     Abstract available
    
    
    March 2024
37. KANAOKA S, Okabe A, Kanesaka M, Rahmutulla B, et al
    Chromatin activation with H3K36me2 and compartment shift in metastatic castration-resistant prostate cancer.
    Cancer Lett. 2024;588:216815.
    PubMed     Abstract available
    
    
    
38. RODRIGO-FAUS M, Vincelle-Nieto A, Vidal N, Puente J, et al
    CRISPR/Cas9 screenings unearth protein arginine methyltransferase 7 as a novel essential gene in prostate cancer metastasis.
    Cancer Lett. 2024 Mar 1:216776. doi: 10.1016/j.canlet.2024.216776.
    PubMed     Abstract available
    
    
    February 2024
39. WEI Z, Zhang C, Song Y, Han D, et al
    CircUBE3A(2,3,4,5) promotes adenylate-uridylate-rich binding factor 1 nuclear translocation to suppress prostate cancer metastasis.
    Cancer Lett. 2024 Feb 27:216743. doi: 10.1016/j.canlet.2024.216743.
    PubMed     Abstract available
    
    
    
40. YIN W, Chen G, Li Y, Li R, et al
    Identification of a 9-gene signature to enhance biochemical recurrence prediction in primary prostate cancer: A benchmarking study using ten machine learning methods and twelve patient cohorts.
    Cancer Lett. 2024 Feb 21:216739. doi: 10.1016/j.canlet.2024.216739.
    PubMed     Abstract available
    
    
    
41. CHEN H, Dong K, Ding J, Xia J, et al
    CRISPR genome-wide screening identifies PAK1 as a critical driver of ARSI cross-resistance in prostate cancer progression.
    Cancer Lett. 2024 Feb 14:216725. doi: 10.1016/j.canlet.2024.216725.
    PubMed     Abstract available
    
    
    
42. ZHAO G, Forn-Cuni G, Scheers M, Lindenbergh PP, et al
    Simultaneous targeting of AMPK and mTOR is a novel therapeutic strategy against prostate cancer.
    Cancer Lett. 2024 Feb 7:216657. doi: 10.1016/j.canlet.2024.216657.
    PubMed     Abstract available
    
    
    January 2024
43. SAEZ-MARTINEZ P, Porcel-Pastrana F, Montero-Hidalgo AJ, Lozano de la Haba S, et al
    Dysregulation of RNA-Exosome machinery is directly linked to major cancer hallmarks in prostate cancer: Oncogenic role of PABPN1.
    Cancer Lett. 2024 Jan 18:216604. doi: 10.1016/j.canlet.2023.216604.
    PubMed     Abstract available
    
    
    November 2023
44. ALSAMRAAE M, Costanzo-Garvey D, Teply BA, Boyle S, et al
    Androgen receptor inhibition suppresses anti-tumor neutrophil response against bone metastatic prostate cancer via regulation of TbetaRI expression.
    Cancer Lett. 2023 Nov 6:216468. doi: 10.1016/j.canlet.2023.216468.
    PubMed     Abstract available
    
    
    October 2023
45. WANG C, Wang T, Li KJ, Hu LH, et al
    SETD4 inhibits prostate cancer development by promoting H3K27me3-mediated NUPR1 transcriptional repression and cell cycle arrest.
    Cancer Lett. 2023 Oct 23:216464. doi: 10.1016/j.canlet.2023.216464.
    PubMed     Abstract available
    
    
    September 2023
46. SLOOTBEEK PHJ, Overbeek JK, Ligtenberg MJL, van Erp NP, et al
    PARPing up the right tree; an overview of PARP inhibitors for metastatic castration-resistant prostate cancer.
    Cancer Lett. 2023 Sep 7:216367. doi: 10.1016/j.canlet.2023.216367.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum